

Center for Vaccine
Ethics and Policy



Vaccines and Global Health: The Week in Review
28 November 2020 :: Number 582
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full-text searching of over 9,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents *[click on link below to move to associated content]*

- A. [Milestones :: Perspectives :: Featured Journal Content](#)
- B. [Emergencies](#)
- C. [WHO; CDC \[U.S., Africa, China\]](#)
- D. [Announcements](#)
- E. [Journal Watch](#)
- F. [Media Watch](#)

.....
.....

Milestones :: Perspectives :: Research

.....
.....

Gavi [to 28 Nov 2020]

<https://www.gavi.org/>

News releases

24 November 2020

Gavi and IOM join forces to improve immunisation coverage for migrants

:: Memorandum of understanding signed today will strengthen collaboration on vaccination efforts and related health services for migrants and forcibly displaced persons across the world

:: The agreement focuses on reaching missed communities in humanitarian and emergency settings with vaccination

:: Dr Seth Berkley: Reaching migrant, refugee and displaced populations "becomes all the more important as we plan to rollout COVID-19 vaccines worldwide."

:: António Vitorino: Vaccines are key to keep people on the move and the communities they live in as safe as possible.

Geneva, 24 November 2020 – Today, Gavi the Vaccine Alliance and the International Organization for Migration (IOM) signed a memorandum of understanding to strengthen their collaboration on vaccination efforts and related health services for migrants and forcibly displaced persons across the world, both regarding routine immunisations as well as in response to outbreaks. This milestone will be particularly critical in ensuring that migrants and other people on the move are considered and included, as the world continues its efforts to find a safe COVID-19 vaccine and is developing mechanisms, such as the COVAX Facility, to ensure a fair distribution so that as many lives as possible can be saved.

"Despite enormous progress over the past two decades ensuring children everywhere have access to lifesaving vaccines, **14 million children every year still miss out on basic vaccines,**" said Gavi CEO **Dr Seth Berkley**. **"We know a disproportionate amount of these unprotected children come from migrant, refugee and displaced populations, who are too often overlooked when it comes to basic health care. This obviously becomes all the more important as we plan to rollout COVID-19 vaccines worldwide; we cannot allow these populations to miss out on what could be one of our best routes out of this pandemic.** That's why we're delighted to partner with IOM, to help provide a healthier future to some of the most vulnerable people on earth."

"Vaccines are one of the most powerful tools we have to keep people on the move, the communities they leave behind and the communities they join as safe and healthy as possible," stressed IOM Director General António Vitorino. "This reinforced partnership will be critical in helping IOM achieve just that and contribute tangibly to the realization of true universal health coverage."

The agreement signed by the two organizations focuses on reaching missed communities in humanitarian and emergency settings with vaccination and support routine

immunisation through engagement in primary health care systems. The partnership also aims to boost advocacy for the prioritization of vulnerable populations, support operational and policy assistance and facilitate technical collaboration. **Specifically, the memorandum of understanding seeks to facilitate collaboration on ensuring the inclusion of migrants, IDPs and refugees in governments' COVID-19 responses, in particular vaccination efforts...**

.....
.....

COVID-19 Vaccines – Trials/Development

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

Statement on continuation of vaccine trials

We, (ICMRA members, a global coalition of medicine regulators) have an important role in supporting the worldwide effort to ensure the quality, safety and efficacy of licensed vaccines and to make them available to the public. We have stepped up our global collaboration to facilitate and expedite the development and evaluation of vaccines against SARS-CoV2 (causing COVID-19 disease).

This statement in support of continuing COVID-19 vaccine trials to collect critical data to support regulatory actions and deployment, for as long as is feasible, is intended for all stakeholders, vaccinees, researchers and investigators, academia, regulators and the pharmaceutical industry.

The pandemic represents a major global unsolved public health and economic crisis, which is still far from being under control as we see peaks of transmission, morbidity and mortality over time in different locations. The availability of safe and effective vaccines is anticipated to be an important component of the overall response to the emergency and to contribute to a return to normality.

Regulators have set up flexible and agile procedures to facilitate the swift analysis of clinical trial results submitted to them. These analyses will support clear, independent and transparent benefit-risk evaluations, leading to decisions on the approval of, or early access to, safe and effective vaccines against COVID-19.

To determine that the benefit of a vaccine outweighs its potential risk, regulators need robust and convincing evidence of the safety and efficacy that is obtained from well-designed randomised and controlled trials. Initial positive evidence of the vaccine's safety and efficacy used to support a regulatory action may be based on planned interim or final analyses that occur when a pre-defined number of cases of COVID-19 disease have occurred in a clinical trial. **In these situations, it will be of the utmost importance to continue gathering data about the vaccine safety and efficacy in the longer-term after the interim or final analysis is completed.**

Specifically, continued follow-up of clinical trial participants after a regulatory decision has been made can provide important additional and more precise information on longer-term safety and efficacy against specific aspects of SARS-CoV-2 disease or infection, including efficacy against severe disease, efficacy in important subgroups, potential risks of vaccine-

induced enhanced disease and whether protection against COVID-19 disease wanes over time.

Thus, continued evaluation of the vaccinated and the unvaccinated (control subjects who do not receive a vaccine against COVID-19) groups in clinical trials for as long as feasible will provide invaluable information.

For these reasons, investigators and sponsors should develop strategies to ensure continuation of follow-up of vaccinated and control groups for as long as possible after any regulatory approval that is based on planned analyses conducted while trials are still ongoing and after final analyses are completed.

Therefore, unless maintaining participants in their randomised treatment groups (vaccinated or control) after a vaccine is approved is clearly infeasible, we recommend that clinical trials should proceed as initially planned with a follow-up of at least one year or more from completion of assigned doses. In making this recommendation, we recognise that the feasibility of maintaining the group assignment for at least one year will depend on factors such as the population enrolled into a trial (e.g. in terms of whether they are young and healthy or have reasons to be predisposed to develop severe COVID-19), informed decisions made by clinical trial participants, the availability of COVID-19 vaccine(s), and the characteristics of SARS-CoV-2 epidemics. It will be necessary for sponsors, investigators, public health authorities and regulators to assess each situation that may arise.

.....
.....

COVID-19 Vaccines Regulatory Processes :: Announcements/Meeting Dates/Milestones

Week of 23 November 2020

CHINA - [Leading vaccine maker seeks market approval](#)

2020-11-26

Leading COVID-19 vaccine developer Sinopharm has submitted a market approval application to China's top market regulator, Xinhua News Agency quoted the company's Deputy General Manager Shi Shengyi as saying on Nov 25.

The Chinese company has two experimental COVID-19 vaccines - both of which are the inactivated type - undergoing Phase 3 clinical trials overseas.

The Xinhua report did not reveal details about the application.

.....

Week of 30 November 2020

U.K. - [UK set to approve Pfizer-BioNTech Covid vaccine within days](#)

Rollout of two-shot jab could begin as soon as December 7

28 November 2020 [Sebastian Payne](#) and [Donato Paolo Mancini](#)

The UK is poised to become the first western country to approve a Covid-19 vaccine, with the independent regulator set to grant approval within days. Deliveries of the vaccine developed by BioNTech and Pfizer would begin within hours of the authorisation, according to government officials. The first injections could take place from December 7. The UK has ordered 40m doses of the two-shot

product, which preliminary data found to be more than 95 per cent effective in preventing disease. Vaccines would normally be authorised by the European Medicines Agency until the end of the Brexit transition on December 31. However the UK's Medicines and Healthcare Products Regulatory Agency has the power to temporarily authorise products, in cases of urgent public need...

UK MHRA [Medicines and Healthcare products Regulatory Agency](#)

:: [Pfizer/BioNTech COVID-19 vaccine: MHRA statement](#) 23 November 2020

...Approval process for a potential COVID-19 vaccine

:: Until the end of December, and as part of the transition period, COVID-19 vaccine candidates can be licensed (authorised) via the European Medicines Agency (EMA) and that authorisation will automatically be valid in the UK.

:: However, if a suitable COVID-19 vaccine candidate, with strong supporting evidence of safety, quality and effectiveness from clinical trials becomes available before the end of the transition period, EU legislation allows for temporary authorisation of supply in the UK, based on the public health need.

:: The MHRA will evaluate the data rigorously for quality, safety and effectiveness to reach an independent, scientifically robust opinion. The data must include results from lab and clinical trials in humans; manufacturing and quality controls, product sampling, and testing of the final product.

:: Any COVID-19 vaccine candidate submitted after the transition period ends in January 2021 will not need to go through a European marketing authorisation for use in Great Britain and will instead be assessed directly by the MHRA. The MHRA is globally recognised for requiring the highest standards of safety, quality and effectiveness for any vaccine.

.....

1 December 2020 – Tuesday – 1400-1700/New York [Advisory Committee on Immunization Practices \(ACIP\)](#)

Webcast: December 1, 2020 meeting is a virtual meeting. No registration is required.

Meeting time, 1400 – 1700 EDT (times subject to change).

[Webcast Link](#)

[Meeting Agenda](#)

Selected Agenda Elements

:: Allocation of initial supplies of COVID-19 vaccine: Phase 1a	Dr. Kathleen Dooling (CDC/NCIRD)
:: Clinical considerations for populations included in Phase 1a	Dr. Sara Oliver (CDC/NCIRD)
:: Post-authorization safety monitoring update	Dr. Tom Shimabukuro (CDC/NCEZID)
:: Public Comment	

VOTE

:: Allocation of initial supplies of COVID-19 vaccine: Phase 1a	Dr. Kathleen Dooling (CDC/NCIRD)
---	----------------------------------

.....

4 December 2020 – Friday – 1300-1700/New York U.S. - [National Vaccine Advisory Committee NVAC Meeting \(Virtual\)](#)

Selected Agenda Elements

OPENING REMARKS

Admiral Brett Giroir, Assistant Secretary for Health

APPROACHES TO INCLUDE PREGNANT WOMEN IN COVID-19 CLINICAL TRIALS

Dr. Sascha Ellington, Centers for Disease Control and Prevention

Dr. Ruth Faden, Johns Hopkins University

Dr. Jeff Roberts, Food and Drug Administration
Dr. Linda Eckert, American College of Obstetricians and Gynecologists
Dr. Titi Oduyebo, Centers for Disease Control and Prevention

VACCINE SAFETY SYSTEMS AND COVID-19

Dr. Peter Marks, Food and Drug Administration
Dr. Arnold Monto, Vaccines and Related Biological Products Advisory Committee
Dr. Tom Shimabukuro, Centers for Disease Control and Prevention
Dr. Sonali Kochhar, University of Washington

REGISTER: <https://www.hhs.gov/webforms/nvac/index.html>

.....

10 December 2020 – Thursday – 0900-1800/New York

[FDA - Vaccines and Related Biological Products Advisory Committee](#)

The FDA's Center for Biologics Evaluation and Research's Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet in **open session to discuss Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine** for the prevention of COVID-19 in individuals 16 years of age and older.

Webcast Information

CBER plans to provide a free of charge, live webcast of the Vaccines and Related Biological Products Advisory Committee meeting. If there are instances where the webcast transmission is not successful; staff will work to re-establish the transmission as soon as possible. The online web conference meeting will be available at the following:

<https://youtu.be/owveMJBTc2I>[External Link Disclaimer](#)

https://twitter.com/US_FDA[External Link Disclaimer](#) (Supported in Chrome browser)

<https://fda.yorkcast.com/webcast/Play/d75d80a3eb6e419986181c1a881fe2671d>.

.....

11 December 2020 – Thursday – 1300-1630/CET

[EMA Public stakeholder meeting: development and authorisation of safe and effective COVID-19 vaccines in the EU](#)

:: [Agenda - EMA public stakeholder meeting on COVID-19 \(PDF/310.91 KB\) \(new\)](#)

:: [Documents](#)

:: [Live broadcast](#)

EMA is organising this virtual meeting to explain the processes for the development, evaluation, approval and safety monitoring of COVID-19 vaccines in the EU, including EMA's specific role, to all interested parties.

It will also give the opportunity to the public and stakeholder groups to speak and share their needs, expectations and any concerns, that will be considered by EMA and the European medicines regulatory network in the decision-making process.

Please note that some issues of high public interest, such as patient access to COVID-19 vaccines and national vaccination campaigns, lie outside EMA's remit and will not be covered at this event.

[EMA starts rolling review of mRNA COVID-19 vaccine by Moderna Biotech Spain, S.L.](#)

Last updated: 16/11/2020

EMA's human medicines committee (CHMP) has started a 'rolling review' of data on a vaccine for COVID-19 known as mRNA-1273, which is being developed by Moderna Biotech Spain, S.L. (a

subsidiary of Moderna, Inc.)...The rolling review will continue until enough evidence is available to support a formal marketing authorisation application...

.....
.....

Editor's Note:

To better present a global view of COVID-19 vaccine development, regulatory review, procurement and deployment, we will present headlines from this site – which provides as its contact point the Russian Direct Investment Fund [RDIF].

Sputnik V – “the first registered COVID-19 vaccine” [to 28 Nov 2020]

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

[RDIF and Hetero agree to produce over 100 million doses of the Sputnik V vaccine in India](#)

Press release, 27.11.2020

[The cost of one dose of the Sputnik V vaccine will be less than \\$10 for international markets](#)

Press release, 24.11.2020

[Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose](#)

Press release, 24.11.2020

.....
.....

COVID-19 Vaccines :: Procurement/Distribution/Logistics

[Moderna Announces the European Commission's Approval of Advance Purchase Agreement for Initial 80 Million Doses of mRNA Vaccine Against COVID-19 \(mRNA-1273\)](#)

*Option granted to European Commission to purchase up to an additional 80 million doses
Agreement reflects Moderna's commitment to make its vaccine available in multiple countries*

November 25, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Commission has approved an agreement to secure 80 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, as part of the European Commission's goal to secure access to a safe and effective COVID-19 vaccine for Europe.

Under the terms of the proposed agreement, the European Commission has the option to increase their purchase of mRNA-1273, from 80 million doses to a total of up to 160 million doses. The agreement will be finalized following a brief review period by the European Union Member States. This announcement follows the conclusion of advanced exploratory talks with the European Commission that began on August 24, 2020. Delivery of the vaccine could begin as early as the first quarter 2021 if

it is approved for use by the European Medicines Agency (EMA) human medicines committee (CHMP), which started a rolling review of mRNA-1273 on November 17...

.....

COVAXX Announces \$2.8 Billion in Advance Purchase Commitments to Deliver More Than 140 Million Vaccine Doses to Emerging Countries

:: COVAXX's UB-612 is the only multipeptide, synthetic peptide-based vaccine candidate in the clinic

:: Company's manufacturing facilities in place to produce 100 million doses in 1H 2021 and up to 1 billion by YE 2021

:: UB-612 distribution utilizes normal refrigeration (no freezing required)

:: Company partnered with Maersk for worldwide shipping and logistics

:: Phase 2/3 clinical trials to begin end of 2020/1Q 2021 in Asia, Latin America, and U.S.

November 25, 2020

HAUPPAUGE, N.Y.--(BUSINESS WIRE)--COVAXX, a U.S. company developing a multipeptide vaccine to fight COVID-19, **announces advanced purchase commitments of more than 140 million doses of its UB-612 vaccine, totaling over \$2.8 billion, to deliver vaccines in multiple countries, including Brazil, Ecuador and Peru.** These public and private commitments follow the start of human trials in Taiwan and the September agreement with Diagnosticos da America SA (Dasa S.A.), the largest clinical diagnostic company in Brazil, to conduct Phase 2/3 clinical trials and distribute vaccines within Brazil.

"In parallel with the expedited clinical development of UB-612, we are working to help countries with the greatest unmet needs customize their plans for vaccine studies, supply and distribution," said Mei Mei Hu, co-founder and CEO of COVAXX. "The realistic view of vaccine production is that we will need a wide range of vaccine options utilizing different technologies to meet worldwide demand. As much as vaccines matter, vaccinations matter more. To be administered effectively, vaccines need to demonstrate easy and affordable distribution, durability of response with the capability to further extend it with effective boosts, as well as the ability to adapt to a potential mutation in the virus while building on the first vaccines made available."

COVAXX (not to be confused with single "x" COVAX) is currently completing Phase 1 clinical trials of UB-612 in Taiwan and has an agreement with the University of Nebraska Medical Center (UNMC), home of the National Pandemic Center, to also conduct trials in the U.S. **Last month, COVAXX announced a global logistics partnership with Maersk, the world's largest shipping and integrated logistics provider, that creates a framework for all transportation and supply chain services that will be needed to deliver COVAXX's UB-612 around the world...**

.....

COVAX Update: UNICEF working with global airlines and freight providers to plan delivery of COVID-19 vaccines

UNICEF kickstarts discussions with over 350 logistics organizations to step up delivery plans for eventual COVID-19 vaccines

NEW YORK, 23 November 2020: UNICEF is working with major global airlines and freight providers to step up efforts to deliver COVID-19 vaccines to over 92 countries around the world as soon as vaccines become available.

To kickstart preparations, UNICEF together with the Pan American Health Organization (PAHO) and the International Air Transport Association (IATA), briefed major global airlines last week on the expected capacity requirements and discussed ways to **transport close to 2 billion doses of COVID-19 vaccines in 2021. This is in addition to the 1 billion syringes that need to be transported by sea-freight.**

This virtual meeting comes close on the heels of the first-ever logistics event held virtually by UNICEF to discuss the transportation of COVID-19 vaccines. **The landmark discussion brought together more than 350 logistics partners, including air freight operators, shipping lines and global logistics associations.**

"As work continues to develop COVID-19 vaccines, UNICEF is stepping-up efforts with airlines, freight operators, shipping lines and other logistics associations to deliver life-saving vaccines as quickly and safely as possible," said Etleva Kadilli, Director of UNICEF's Supply Division. "This invaluable collaboration will go a long way to ensure that enough transport capacity is in place for this historic and mammoth operation. We need all hands on deck as we get ready to deliver COVID-19 vaccine doses, syringes and more personal protective equipment to protect front line workers around the globe. By protecting these workers, we are ultimately protecting the millions of children who depend on their critical services."

In the coming weeks, UNICEF is also assessing existing transport capacity to identify gaps and future requirements. **The procurement, delivery and distribution of COVID-19 vaccines is anticipated to be the largest and fastest such operation ever undertaken. UNICEF is leading efforts to procure and deliver vaccines from manufacturers that have agreements with [the COVAX Facility](#). In collaboration with PAHO, UNICEF will coordinate the purchase and delivery for 92 low- and lower middle-income economies as quickly and securely as possible.**

These efforts build on UNICEF's longstanding efforts with the logistics industry to transport supplies around the world despite restrictions related to the pandemic. Since January, UNICEF has delivered more than US\$190 million worth of COVID-19 supplies such as masks, gowns, oxygen concentrators and diagnostic test kits in support of countries as they respond to the pandemic.

As the largest single vaccine buyer in the world, UNICEF normally procures more than 2 billion doses of vaccines annually for routine immunization and outbreak response on behalf of nearly 100 countries. This unparalleled expertise includes the coordination of thousands of shipments with various cold chain requirements, making UNICEF an expert in supply chain management of temperature-controlled products, which is especially needed during this historic undertaking. To minimise disruptions to routine immunization programmes due to the operations related to the COVID-19 vaccines and syringes, UNICEF and partners will continue to coordinate closely with logistics operators for timely delivery around the world.

"The support of governments, partners and the private sector will be paramount to transport vaccines for deadly diseases such as measles, diphtheria and tetanus, as well as for COVID-19, as efficiently as possible," Kadilli said.

Last month, UNICEF began a process to stockpile more than 1 billion syringes by 2021 to guarantee initial supply and pre-position in advance of COVID-19 vaccines.

.....
.....

[Ad Council Launches \\$50 Million Fund for National COVID-19 Vaccine Education Effort](#)

With many Americans not yet committed to getting a COVID-19 vaccine when available, leaders in communications, policy and health unite to create a research-driven public education campaign

NEW YORK, Nov. 23, 2020 /PRNewswire/ -- The Ad Council today announced plans for a communications effort to encourage vaccination against the virus, which will represent one of the largest public education campaigns in history. This effort will be launched in partnership with the COVID Collaborative, a national assembly that has brought together leading experts and institutions across health, education and the economy to turn the tide on the pandemic by supporting state and local officials.

This national initiative will complement government efforts and has set an initial goal of raising \$50 million from the private sector, including the philanthropic community and corporations. This effort will be guided by science and health experts from the COVID Collaborative, amplified by partnerships across every sector and rooted in extensive research with key audiences...

.....
.....

EMERGENCIES

Coronavirus [COVID-19]

Public Health Emergency of International Concern (PHEIC)

Weekly Epidemiological and Operational updates

last update: 14 November 2020, 10:30 GMT-4

Confirmed cases :: 61 299 371 [week ago: 57 274 018] [two weeks ago: 53 164 803]

Confirmed deaths :: 1 439 784 [week ago: 1 368 000] [two weeks ago: 1 300 576]

Countries, areas or territories with cases :: 220

.....

[Weekly epidemiological update - 24 November 2020](#)

Overview

This past week, the global acceleration in case incidence has slowed down, with around 4 million new cases reported; however, death rates continue to increase with over 67 000 new deaths reported.

.....
.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

Polio this week as of 25 November 2020

:: Fahima Ahmed Hassan is a 25-year-old community mobilizer who goes the extra mile to ensure parents of children under the age of five are informed of Somalia's polio vaccination campaigns and are ready for their children to be vaccinated. [Read about Fahima and other Community mobilizers who build trust with communities ahead of crucial vaccination campaigns.](#)

:: The GPEI has published an [Interim guidance document](#) on the use of Novel Oral Polio Vaccine type 2 (nOPV2) which is meant to provide context and policy guidance on the use of nOPV2 in response to Type 2 circulating Vaccine-Derived Poliovirus (cVDPV2) during the Initial Use Period. This document is an addendum to the "Standard Operating Procedures: Responding to a poliovirus event or outbreak", Version 3.1' (SOPs) (5).

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

:: **Afghanistan:** two WPV1 cases, 24 cVDPV2 cases and 18 cVDPV2 positive environmental samples

:: **Pakistan:** two WPV1 positive environmental samples and 21 cVDPV2 cases

:: **Burkina Faso:** four cVDPV2 cases

:: **Côte d'Ivoire:** 16 cVDPV2 cases and 4 cVDPV2 positive environmental samples

:: **Niger:** two cVDPV2 cases

:: **South Sudan:** seven cVDPV2 cases and 2 cVDPV2 positive environmental samples

:: **Sudan:** two cVDPV2 cases

:: **Somalia:** one cVDPV2 case and one cVDPV2 positive environmental sample

:: **Yemen:** two cVDPV1 cases

.....
.....

Editor's Note:

A number of country pages below did not load at inquiry.

WHO Grade 3 Emergencies [to 28 Nov 2020]

[Democratic Republic of the Congo](#) - *No new digest announcements identified*

[Mozambique floods](#) - *No new digest announcements identified*

[Nigeria](#) - *No new digest announcements identified*

[Somalia](#) - *No new digest announcements identified*

[South Sudan](#) - *No new digest announcements identified*

[Syrian Arab Republic](#) - *No new digest announcements identified*

[Yemen](#) - *No new digest announcements identified*

.....

WHO Grade 2 Emergencies [to 28 Nov 2020]

Iraq

:: [Restoration works completed at East Erbil Emergency Hospital and specialized services resumed for patients](#) 24 November 2020

Afghanistan - No new digest announcements identified
Angola - No new digest announcements identified
Burkina Faso - No new digest announcements identified
Burundi - No new digest announcements identified
Cameroon - No new digest announcements identified
Central African Republic - No new digest announcements identified
Ethiopia - No new digest announcements identified
Iran floods 2019 - No new digest announcements identified
Libya - No new digest announcements identified
Malawi Floods - No new digest announcements identified
Measles in Europe - No new digest announcements identified
MERS-CoV - No new digest announcements identified
Mozambique - No new digest announcements identified
Myanmar - No new digest announcements identified
Niger - No new digest announcements identified
occupied Palestinian territory - No new digest announcements identified
HIV in Pakistan - No new digest announcements identified
Sao Tome and Principe Necrotizing Cellulitis (2017) - No new digest announcements identified
Sudan - No new digest announcements identified
Ukraine - No new digest announcements identified
Zimbabwe - No new digest announcements identified

.....

WHO Grade 1 Emergencies [to 28 Nov 2020]

Djibouti

:: Djibouti se prépare aux Journées nationales de vaccination contre la poliomyélite
25 novembre 2020 – Près de 130 000 enfants de Djibouti vont être vaccinés contre le poliovirus dans le cadre d'une campagne de vaccination nationale contre la poliomyélite qui devrait débuter lundi 23 novembre et s'étendra sur quatre jours

Chad - No new digest announcements identified
Kenya - No new digest announcements identified
Mali - No new digest announcements identified
Namibia - viral hepatitis - No new digest announcements identified
Tanzania - No new digest announcements identified

.....

.....

UN OCHA – L3 Emergencies

The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system's classification for the response to the most severe, large-scale humanitarian crises.

Syrian Arab Republic - No new digest announcements identified
Yemen - No new digest announcements identified

.....

UN OCHA – Corporate Emergencies

When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.

East Africa Locust Infestation

:: Desert Locust situation update - 24 November 2020

COVID-19

:: Coronavirus Disease (COVID-19): Weekly Epidemiological Update (24 November 2020)

.....

.....

WHO & Regional Offices [to 28 Nov 2020]

Webinar: a multilateral response to misinformation and data transparency

30 November 2020 15:00 – 17:00 CET

26 November 2020 Departmental news

WHO releases new guidance on integrating mental health in radiological and nuclear emergency response

25 November 2020 News release

Every move counts towards better health – says WHO

25 November 2020 Departmental news

Update: WHO revision of pain management guidelines

23 November 2020 Departmental news

Countdown to 2030 launches expanded 2020 country profiles on early childhood development

23 November 2020 Departmental news

The city of lights glows teal for cervical cancer elimination

.....

Weekly Epidemiological Record 27 November 2020, Vol. 95, No. 48, pp. 585–608

:: Meeting of the Strategic Advisory Group of Experts on Immunization, October 2020 – conclusions and recommendations

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

No new digest content identified

WHO Region of the Americas PAHO

No new digest content identified

WHO South-East Asia Region SEARO

:: Act now to address the shadow pandemic of violence against women

25 November 2020 Statement SEARO

By Dr Poonam Khetrapal Singh, WHO Regional Director for South-East Asia
Urgent action is needed across the WHO South-East Asia Region to strengthen efforts to protect women and girls from violence and to support their health needs amid the ongoing COVID-19 pandemic...

WHO European Region EURO

:: WHO and ECDC call for improved HIV testing in Europe 26-11-2020

:: WHO's Emergency Medical Teams inspire countries and colleagues during the COVID-19 pandemic 25-11-2020

:: COVID-19 update: doing our share, a new horizon with technological and pharmaceutical development, and preserving the rights of children (delivered in Russian) 24-11-2020

:: Health workers at risk, older adults and residents of long-term care facilities to be prioritized for COVID-19 vaccination 23-11-2020

WHO Eastern Mediterranean Region EMRO

:: WHO supports civil/military cooperation on COVID-19 database

26 November 2020 - A collaborative initiative between the Lebanese army and the Ministry of Public Health, supported by WHO, has created a comprehensive database for COVID-19 cases in Lebanon. Dr Iman Shankiti, WHO Representative in Lebanon, accompanied by a WHO team, visited the army hospital in Badaro, Beirut, to review equipment installed by WHO for the project.

This initiative falls under a project to create civil/military cooperation during the pandemic through the exchange of information between the Ministry of Public Health and the Lebanese army on cases and other areas related to the coronavirus. This approach has been pioneered by Lebanon, with WHO providing equipment and training for the army with the support of the Ministry.

WHO Western Pacific Region

No new digest content identified

.....
.....

CDC/ACIP [to 28 Nov 2020]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements

COVID-19 Travel Health Notice Levels and Testing for International Travelers

Sunday, November 22, 2020

...CDC's Travel Health Notices inform travelers and clinicians about current health issues in destinations around the world. For most diseases, the Travel Health Notices have 3 levels. This new 4-level travel health notice system is specific to COVID-19 and details the level of COVID-19 in international destinations and U.S. territories.

Advisory Committee on Immunization Practices (ACIP)

Webcast: December 1, 2020 meeting is a virtual meeting. No registration is required.

Meeting time, 1400 – 1700 EDT (times subject to change).

[Webcast Link](#)

[Meeting Agenda](#)

Coronavirus Disease 2019 (COVID-19)

Selected Resources

:: [The Advisory Committee on Immunization Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020](#) Wednesday, November 25, 2020

:: [How CDC Is Making COVID-19 Vaccine Recommendations](#) Wednesday, November 25, 2020

:: [Frequently Asked Questions about COVID-19 Vaccination](#) Tuesday, November 24, 2020

MMWR News Synopsis Friday, November 27, 2020

:: [Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April–August 2020](#)

:: [Implementation of Hospital Practices Supportive of Breastfeeding in the Context of COVID-19 — United States, July 15–August 20, 2020](#)

:: [COVID-19 Outbreak Associated with a 10-Day Motorcycle Rally in a Neighboring State — Minnesota, August–September 2020 \(Early release November 20, 2020\)](#)

:: [Trends in County-Level COVID-19 Incidence in Counties With and Without a Mask Mandate — Kansas, June 1–August 23, 2020 \(Early release November 20, 2020\)](#)

:: [The Advisory Committee on Immunization Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020 \(Early release November 23, 2020\)](#)

.....

Africa CDC [to 28 Nov 2020]

<http://www.africacdc.org/>

News

#AfricaMaskWeek launches to build continent-wide movement for mask-wearing

ADDIS ABABA, ETHIOPIA, 23 NOVEMBER 2020. #AfricaMaskWeek launches today across the continent, from 23 to 30 November 2020. Led by the Pandemic Action Network, in partnership with the Africa Centres for Disease Control and Prevention (Africa CDC), the African Union Office of the Youth Envoy, the African Youth Front on Coronavirus, Resolve to Save Lives, and many other organizations, this week-long social media campaign will encourage mask-wearing across the African continent...

.....

China CDC

<http://www.chinacdc.cn/en/>

No new digest content identified.

National Health Commission of the People's Republic of China [to 28 Nov 2020]

<http://en.nhc.gov.cn/>

News

Nov 28: Daily briefing on novel coronavirus cases in China

On Nov 27, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 6 new cases of confirmed infections.

[Leading vaccine maker seeks market approval](#)

2020-11-26

Leading COVID-19 vaccine developer Sinopharm has submitted a market approval application to China's top market regulator, Xinhua News Agency quoted the company's Deputy General Manager Shi Shengyi as saying on Nov 25.

The Chinese company has two experimental COVID-19 vaccines - both of which are the inactivated type - undergoing Phase 3 clinical trials overseas.

The Xinhua report did not reveal details about the application.

Liu Jingzhen, chairman of Sinopharm, said previously that hundreds of thousands of people in China have been injected with either one of the vaccines through emergency authorization, and 56,000 of them have traveled abroad after inoculation.

No severe adverse effects have been observed among them, and none of those now living overseas has been infected with the virus, he said.

Regarding the overseas trials, Liu said nearly 60,000 volunteers from 10 countries have been enrolled in the program, and preliminary results are satisfactory.

The company's production capability is expected to exceed 1 billion doses by the end of next year. China now has five COVID-19 vaccines in Phase 3 clinical trials in foreign countries, making it a front-runner in the global race to create a safe, effective vaccine.

National Medical Products Administration [to 28 Nov 2020]

<http://english.nmpa.gov.cn/news.html>

News

[Leading vaccine maker seeks market approval](#)

2020-11-26

[See above]

.....

.....

Announcements

Paul G. Allen Frontiers Group [to 28 Nov 2020]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

News

No new digest content identified.

BARDA – U.S. Department of HHS [to 28 Nov 2020]

<https://www.phe.gov/about/barda/Pages/default.aspx>

BARDA News

No new digest content identified.

BMGF - Gates Foundation [to 28 Nov 2020]

<http://www.gatesfoundation.org/Media-Center/Press-Releases>

Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 28 Nov 2020]

<https://www.gatesmri.org/>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.

CARB-X [to 28 Nov 2020]

<https://carb-x.org/>

News

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 28 Nov 2020]

<http://cepi.net/>

Latest News

[The Republic of Korea provides US \\$9 million contribution to CEPI to advance vaccine development and prepare for future outbreaks](#)

The financial contribution was announced at a virtual signing ceremony attended by Ambassador Nam, Head of the Embassy of the Republic of Korea to Norway, and CEPI CEO, Dr. Richard Hatchett.
COVID-19 25 Nov 2020

[Ensuring safety of COVID-19 vaccines](#)

Dr Robert Chen, leading vaccine-safety expert, discusses the importance of safety monitoring for COVID-19 vaccines
COVAX 24 Nov 2020

[Indonesia donates US \\$1 million to further CEPI's vaccine research and combat epidemic threats](#)

The financial contribution will further vaccine programmes against CEPI's target diseases.
COVAX 24 Nov 2020

[CEPI welcomes University of Oxford / AstraZeneca encouraging interim COVID-19 vaccine efficacy data](#)

"It is terrific to see another approach to vaccine development also yielding such positive findings on an interim analysis," says CEPI CEO, Richard Hatchett.
23 Nov 2020

EDCTP [to 28 Nov 2020]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

Latest news

24 November 2020

Largest clinical trial in Africa to treat mild to moderate COVID-19 patients launched in 13 countries

Thirteen African countries and an international network of research institutions have joined forces to launch the largest clinical trial in mild-to-moderate COVID-19 outpatients in Africa. The ANTICOV clinical trial aims to identify treatments for these cases and thus to contribute to the prevention of spikes in hospitalisation that could overwhelm health systems in Africa.*

The trial will be conducted by the ANTICOV consortium. It includes 26 prominent African and global R&D organisations. It is coordinated by the Drugs for Neglected Diseases initiative (DNDi).

Funding

Major funding for the ANTICOV consortium is provided by the German Federal Ministry of Education and Research (BMBF) and by the global health agency Unitaid. Early support to launch the initiative was provided by EDCTP under its Covid-19 Emergency call with additional funding from the Swedish government, and the Starr International Foundation, Switzerland. This funding contributed to finalising the study protocol and facilitating expedited reviews by in-country regulatory and ethics authorities. It also supported the timely preparation of trial sites in selected African countries and a robust, standardised data management system.

Study approach

ANTICOV clinical trials will be carried out at 19 sites in Burkina Faso, Cameroon, Côte d'Ivoire, the Democratic Republic of Congo (DRC), Equatorial Guinea, Ethiopia, Ghana, Guinea, Kenya, Mali, Mozambique, Sudan, and Uganda. The study is an open-label, randomised, comparative, 'adaptive platform trial' that will test the safety and efficacy of treatments in 2,000 to 3,000 mild-to-moderate COVID-19 patients. The adaptive platform trial is an innovative type of clinical trial pioneered for cancer drugs. It allows for several treatments to be tested simultaneously. Adaptive platform trials enable rapid decisions based on the ongoing analysis of results.

The study will begin testing, against a control arm, the HIV antiretroviral combination lopinavir/ritonavir and the malaria drug hydroxychloroquine, which remains the standard of care for COVID-19 today in numerous African countries.

All clinical trial data generated by ANTICOV will be integrated and shared openly and transparently to inform public health policy. Every effort will be made to work with all relevant partners to ensure that treatments that prove safe and effective will be affordable, available, and accessible for all...

Emory Vaccine Center [to 28 Nov 2020]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Medicines Agency [to 28 Nov 2020]

<http://www.ema.europa.eu/ema/>

News & Press Releases

[News: Global regulators urge continuation of COVID-19 vaccine trials for longer-term safety and efficacy follow-up](#)

Last updated: 27/11/2020

[News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee \(PRAC\) 23-26 November 2020](#)

PRAC, Last updated: 27/11/2020

[News: Call for expressions of interest for Committee for Orphan Medicinal Products \(COMP\) members positions representing patient organisations](#)

COMP, Last updated: 24/11/2020

[News: Workshop on regulatory support for development of orphan medicines](#)

COMP, Last updated: 23/11/2020

On Monday, 30 November, EMA is hosting a workshop to discuss the benefits and impact of early regulatory interactions and incentives for the development of medicines for rare diseases.

European Vaccine Initiative [to 28 Nov 2020]

<http://www.euvaccine.eu/>

Latest News

Nov 16, 2020

[RICH Symposium on "Research Infrastructures as Engines for Maximising Impact of Horizon Europe](#)

The RICH Symposium on "Research Infrastructures as Engines for Maximising Impact of Horizon Europe" brought together around 180 participants in the session dedicated to Health & Food. Speakers -including representatives from the European Commission and different Research Infrastructures initiatives- shared their views and expectations regarding how Research Infrastructures could become key components of the Horizon Europe Missions and other parts of the upcoming framework programme...

FDA [to 28 Nov 2020]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

Press Announcements / Selected Details

[November 25, 2020 - Coronavirus \(COVID-19\) Update: FDA Issues New Policy on Dry Heat for Reuse of Certain Respirators](#)

[November 24, 2020 - Coronavirus \(COVID-19\) Update: November 24, 2020](#)

...Also today, the FDA posted [two templates](#) with recommendations on what to include in EUA requests for serology tests. These templates provide the FDA's current recommendations on what data and information should be submitted to the FDA in support of an EUA request or Pre-EUA submission for a SARS-CoV-2 antibody test or home specimen collection devices using dried blood spot. The ..FDA, but alternative approaches can be used...

November 23, 2020 - Coronavirus (COVID-19) Update: November 23, 2020

...The FDA also recently posted a new infographic, The Path for a COVID-19 Vaccine from Research to Emergency Use Authorization, to explain a potential pathway for vaccines.

November 23, 2020 - FDA Expands Approval of Influenza Treatment to Post-Exposure Prevention

...“This expanded indication for Xofluza will provide an important option to help prevent influenza just in time for a flu season that is anticipated to be unlike any other because it will coincide with the coronavirus pandemic,” said Debra Birnkrant, M.D., director of the Division of Antiviral Products in the FDA’s Center for Drug Evaluation and Research. “Americans will have to be more vigilant than ever as these viruses spread concurrently.”...

November 21, 2020 - Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19. This includes those who are 65 years of age or older or who have certain chronic medical conditions.

...“The FDA remains committed to advancing the nation’s public health during this unprecedented pandemic. Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system,” said FDA Commissioner Stephen M. Hahn, M.D. “As part of our Coronavirus Treatment Acceleration Program, the FDA uses every possible pathway to make new treatments available to patients as quickly as possible while continuing to study the safety and effectiveness of these treatments.”

Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses. Casirivimab and imdevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells.

“The emergency authorization of these monoclonal antibodies administered together offers health care providers another tool in combating the pandemic,” said Patrizia Cavazzoni, M.D., acting director of the FDA’s Center for Drug Evaluation and Research. “We will continue to facilitate the development, evaluation and availability of COVID-19 therapies.”...

FDA - COVID-19 Vaccines [to 28 Nov 2020]

www.fda.gov/covid19vaccines

Upcoming Events

Vaccines and Related Biological Products Advisory Committee

12/10/2020

The FDA’s Center for Biologics Evaluation and Research’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet in open session to discuss Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 in individuals 16 years of age and older.

Fondation Merieux [to 28 Nov 2020]

<http://www.fondation-merieux.org/>

News, Events

Mérieux Foundation co-organized event

[7th Meeting of the GTFCC Working Group on Oral Cholera Vaccine Webinars](#)

November 19 - December 10, 2020 - Webinars

Gavi [to 28 Nov 2020]

<https://www.gavi.org/>

News releases

24 November 2020

[Gavi and IOM join forces to improve immunisation coverage for migrants](#)

Memorandum of understanding signed today will strengthen collaboration on vaccination efforts and related health services for migrants and forcibly displaced persons across the world

[See Milestones above for detail]

24 November 2020

[Gavi statement on AstraZeneca/Oxford interim efficacy data](#)

GHIT Fund [to 28 Nov 2020]

<https://www.ghitfund.org/newsroom/press>

GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

Global Fund [to 28 Nov 2020]

<https://www.theglobalfund.org/en/news/>

News

[44th Board Meeting Documents](#)

26 November 2020

The Board of the Global Fund held its Forty-Fourth Meeting on 11-12 November 2020. Documents from the meeting are now available on the [44th Board Meeting](#) page.

[COVID-19 Situation Report](#)

24 November 2020

A new issue of the COVID-19 Situation Report is available: Situation Report - 24 November 2020 download in [English](#)

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 28 Nov 2020]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 28 Nov 2020]

<http://www.hillemanlabs.org/>

No new digest content identified.

Human Vaccines Project [to 28 Nov 2020]

<http://www.humanvaccinesproject.org/media/press-releases/>

Press Releases

[Special Issue 3: Interim Efficacy Results Reported for Third COVID-19 Vaccine Candidate](#)

Nov 23, 2020

By Wayne Koff, Ph.D.

President & CEO

AstraZeneca announced results today from an interim analysis of its COVID-19 vaccine candidate that indicate the vaccine is 70% effective on average, according to an ongoing Phase III trial in the U.K. and Brazil. The vaccine candidate is the first of the viral vector platform vaccines to demonstrate efficacy, using an adenovirus that commonly infects chimpanzees to express the SARS-CoV-2 Spike (S) protein. This vaccine was developed in partnership with Oxford University and its spin-off Vaccitech. Both [Pfizer/BioNTech](#) and [Moderna](#) recently released interim efficacy results for their vaccine candidates, both of which are based on mRNA strategies for delivering vaccine antigens

IAVI [to 28 Nov 2020]

<https://www.iavi.org/newsroom>

PRESS RELEASES/FEATURES

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

[Statement on continuation of vaccine trials](#)

Undated – presume week of 23 Nov 2020

[See COVID-19 Vaccine Development above for detail]

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 28 Nov 2020]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

Asia Pacific, Philippines

[Typhoon crisis: 305,000 houses wrecked in Philippines](#)

Kuala Lumpur/Manila/Geneva, 26 November 2020 – Consecutive, devastating typhoons in the Philippines have laid the foundations for a long-term humanitarian crisis as more than 305,000 homes have been damaged or destroyed according to humanitarian assess ...

26 November 2020

Africa, Ethiopia, Sudan

[Sudan: Red Crescent ramps up operation as influx of Ethiopian refugees grows](#)

Khartoum/Nairobi/Geneva, 23 November 2020 – The Sudanese Red Crescent Society has scaled up its operation at the border with Ethiopia to support the growing number of Ethiopian refugees coming into the country. Since fighting began in Ethiopia's Tigray ...

24 November 2020

Institut Pasteur [to 28 Nov 2020]

<https://www.pasteur.fr/en/press-area>

Press documents

Press Info

19.11.2020

[COVID-19: neutralizing immune response lasts longer in women than in men](#)

As part of the SEROCov-HUS study, teams from Strasbourg University Hospital and the Institut Pasteur monitored 308 hospital staff who had previously contracted a mild form of SARS-CoV-2. The scientists demonstrated that neutralizing antibodies could be detected in 84% of them up to 6 months after infection, but that the level fell more quickly in men than in women. These results seem to suggest that immunity lasts longer in women than in men. The study was published as a preprint on the MedRxiv website.

IRC International Rescue Committee [to 28 Nov 2020]

<http://www.rescue.org/press-release-index>

Media highlights [Selected]

Statement

[As tensions rise in Mekelle, Ethiopia, IRC warns of impending humanitarian disaster](#)

November 27, 2020

Press Release

[IRC welcomes President-Elect Biden's foreign policy team, urges pressing humanitarian action](#)

November 23, 2020

Press Release

[Humanitarian needs in Afghanistan skyrocket amid unrelenting violence and the pandemic; ahead of peace conference, IRC calls on international community to increase funding and push for peace](#)

November 23, 2020

IVAC [to 28 Nov 2020]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 28 Nov 2020]

<http://www.ivi.int/>

Selected IVI News, Announcements, Events

[IVI, ROK's GDEF join forces to provide OCV vaccination to 540,000 people at risk of cholera in Nepal and Mozambique](#)

GDEF's US\$8.05 million grant to support ECHO projects to prevent and control cholera and contribute to 'Ending Cholera—A Global Roadmap to 2030' The International Vaccine Institute (IVI) and the Republic of Korea's Global Disease Eradication Fund (GDEF) have agreed to conduct joint projects to [...] 11/26/2020

[IVI and the Ministry of Foreign Affairs and Human Mobility of Ecuador exchange MOU to pursue global health research & development](#)

November 24, 2020, SEOUL, Republic of Korea — The International Vaccine Institute (IVI) and the Ministry of Foreign Affairs and Human Mobility of Ecuador exchanged a memorandum of understanding (MOU) today at IVI headquarters in Seoul, Republic of Korea to explore areas of collaboration in [...] 11/24/2020

[LG Electronics, IVI join forces to conduct a 'cholera vaccination and prevention project' in Ethiopia](#)

Project to provide vaccination for 40,000 residents in areas at risk of cholera and establish disease monitoring system with the Ethiopian Ministry of Health through the Armauer Hansen Research Institute (AHRI) To contribute to health authorities in policymaking for disease prevention by investigating waterborne diseases [...] 11/24/2020

JEE Alliance [to 28 Nov 2020]

<https://www.jeealliance.org/>

Selected News and Events

No new digest content identified.

MSF/Médecins Sans Frontières [to 28 Nov 2020]

<http://www.msf.org/>

Latest [Selected Announcements]

Sudan

[MSF providing medical care and assistance in Sudan to people fleein...](#)

Project Update 27 Nov 2020

Iraq

[Displaced people in Iraq's Laylan camp express fears as camp ...](#)

Press Release 24 Nov 2020

Coronavirus COVID-19 pandemic

[Staff entry restrictions forces MSF to withdraw from COVID-19 response in Venezuela hospital](#)

:: Entry and work permit restrictions for MSF international staff in Venezuela have made it difficult to continue our work on COVID-19.

:: As a result, MSF has been forced to withdraw from the coronavirus COVID-19 response in the Ana Francisca Pérez de León II hospital, Caracas.

:: MSF urges Venezuelan authorities to facilitate the entry of essential international staff into Venezuela to ensure high-level care in the COVID-19 response.

National Vaccine Program Office - U.S. HHS [to 28 Nov 2020]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings

[December 4, 2020 NVAC Meeting \(Virtual\)](#)

[See COVID Vaccines Regulatory Meetings/Milestones above]

NIH [to 28 Nov 2020]

<http://www.nih.gov/news-events/news-releases>

News Releases

[Fourth iteration of COVID-19 treatment trial underway](#)

November 25, 2020 — Study will enroll hospitalized adults with COVID-19 who require supplemental oxygen.

[Commonly used antibiotic shows promise for combating Zika infections](#)

November 24, 2020 — NIH preclinical study suggests FDA-approved tetracycline-based antibiotics may slow infection and reduce neurological problems.

PATH [to 28 Nov 2020]

<https://www.path.org/media-center/>

Press Release

No new digest content identified.

Sabin Vaccine Institute [to 28 Nov 2020]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 28 Nov 2020]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

27 November 2020

[Study shows how COVID-19 is impacting access to HIV care in the Russian Federation](#)

25 November 2020

[New awareness campaign on gender-based violence in the Middle East and North Africa](#)

24 November 2020

[Turning around the HIV response in Odessa](#)

23 November 2020

[Condom use declining](#)

UNICEF [to 28 Nov 2020]

<https://www.unicef.org/media/press-releases>

Selected Press releases, Statements

Statement

11/25/2020

[Threat of further escalation in Mekelle, Ethiopia, puts children's lives at risk](#)

Statement by UNICEF Executive Director Henrietta Fore

Press release

11/25/2020

[320,000 children and adolescents newly infected with HIV in 2019, 1 every 100 seconds – UNICEF](#)

UNICEF warns of COVID-19 disruptions to HIV service delivery in one third of high burden countries

News note

11/23/2020

[COVAX Update: UNICEF working with global airlines and freight providers to plan delivery of COVID-19 vaccines](#)

UNICEF kickstarts discussions with over 350 logistics organizations to step up delivery plans for eventual COVID-19 vaccines

[See COVID Logistics above for details]

Statement

11/23/2020

[Millions of children's lives at high risk as Yemen inches towards famine](#)

Statement by UNICEF Executive Director Henrietta Fore

Unitaid [to 28 Nov 2020]

<https://unitaid.org/>

Featured News

24 November 2020

[Unitaid supports ANTICOV, an adaptative platform trial in Africa to treat mild to moderate cases of COVID-19](#)

Geneva – Unitaid has come together with the German Federal Ministry of Education and Research (BMBF) and the KfW Development Bank to invest in a ground-breaking clinical trial of COVID-19 medicines that are adapted to the needs of low-and middle-income countries.

This innovative trial named ANTICOV will cover 13 countries across Africa and be implemented by a consortium of partners led by Drugs for Neglected Diseases Initiative (DNDi) including 26 African and global research and development organizations.

It seeks to identify treatments that prevent patients with mild to moderate symptoms from progressing to severe disease, thereby reducing transmission of the virus and the need for hospitalisation.

Both outcomes are particularly important in countries with weaker health systems and where quarantine is difficult to implement. Importantly, ANTICOV will look at treatment options for vulnerable people, such as those with coinfections including HIV, TB and malaria.

Most research into COVID-19 medicines is taking place in high-income countries, thereby limiting the development and relevant testing of products adapted to lower-income settings.

Dr. Philippe Duneton, Unitaid's Executive Director said: "ANTICOV is an important platform to facilitate clinical trials for treatments for COVID-19 in low-resource settings. This is recognised as a key issue by the ACT-A Therapeutics partnership led by Unitaid and Wellcome and will help enable equitable access to medicines against COVID-19 in low- and middle-income countries. Unitaid is pleased to support this important project."

The trial will evaluate affordable treatments that are already in the market and can be quickly deployed on a large scale. The ultimate goal is to put forward candidate medicines for treatment of mild COVID-19 disease, inform WHO recommendations with conclusive evidence, and support policy change towards test-and-treat strategies for the virus across low- and middle-income countries...

Vaccination Acceptance Research Network (VARN) [to 28 Nov 2020]

<https://vaccineacceptance.org/news.html#header1-2r>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 28 Nov 2020]

<http://www.vaccineconfidence.org/>

Research and Reports

No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 28 Nov 2020]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 28 Nov 2020]

<https://wellcome.ac.uk/news>

No new digest content identified.

The Wistar Institute [to 28 Nov 2020]
<https://www.wistar.org/news/press-releases>
Press Releases
No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 28 Nov 2020]
<https://www.wfpha.org/>
Latest News

[Producing a Safe and Effective Vaccine: Align Public Health Needs with Economic & Social Development Objectives](#)

Nov 25, 2020

Producing a Safe and Effective Vaccine: Align Public Health Needs with Economic & Social Development Objectives Webinar recording: <https://www.youtube.com/watch?v=nIYiXfIOYIo&t=498s>

[Sheila Tlou Joins Our International Immunization Policy Task Force!](#)

Nov 24, 2020

Sheila Tlou Joins Our International Immunization Policy Task Force! A warm welcome to Prof. Sheila Dinotshe Tlou Co-Chair of The Global HIV Prevention Coalition & Nursing Now on joining WFPHA's International Immunization Policy Task Force of key...

World Organisation for Animal Health (OIE) [to 28 Nov 2020]
<https://www.oie.int/en/for-the-media/press-releases/2020/>
No new digest content identified.

.....

ARM [Alliance for Regenerative Medicine] [to 28 Nov 2020]
<https://alliancerm.org/press-releases/>
Press Releases

[ARM Responds to EU Pharmaceutical Strategy](#)

November 25, 2020 Washington, DC

The EU Pharmaceutical Strategy recognizes cell and gene therapies as 'major milestones' of progress in healthcare, which can durably treat or even cure the most challenging diseases. We are reviewing today's strategy document in detail and believe that innovative regulatory and payment policies are crucial to ensuring patient access to these transformative therapies. We look forward to engaging with the European Commission and other stakeholders to develop a conducive, holistic environment for advanced therapies and the life-changing benefits they bring to patients.

BIO [to 28 Nov 2020]
<https://www.bio.org/press-releases>
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 28 Nov 2020]

<http://www.dcvmn.org/>
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 28 Nov 2020]

<https://internationalbiotech.org/news/>
News
No new digest content identified.

IFPMA [to 28 Nov 2020]

<http://www.ifpma.org/resources/news-releases/>
Selected Press Releases, Statements, Publications
No new digest content identified.

PhRMA [to 28 Nov 2020]

<http://www.phrma.org/>
Selected Press Releases, Statements

[PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence](#)

November 24, 2020

Systemic racism is as real as any disease, and our industry is not immune. This summer, in the wake of a national outcry for racial and social justice, our industry offered a firm stance – systemic racism is a disease. As a pharmacist and public health researcher whose motivation stems from advancing health equity – this statement makes me ponder the question, how can our industry help break the harmful patterns of racial inequities?

Press Release

[PhRMA Names Debra DeShong Executive Vice President of Public Affairs](#)

November 23, 2020

The Pharmaceutical Research and Manufacturers of America (PhRMA) today named Debra DeShong as executive vice president of public affairs. DeShong will assume the role in mid-December.

Press Release

[Committing to diversity, equity and inclusion: A call to action for clinical trials](#)

November 19, 2020

Guest post from Dr. Barbara Bierer, faculty director of the Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard (MRCT Center), a Professor of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston and a hematologist/oncologist.

The COVID-19 pandemic is the worst public health emergency the world has encountered in over a century and one that has universally impacted the social, political, economic and medical fabric of our lives; it has also exposed significant and systemic health disparities in health care. The disproportionate rates of infection and of disease-related mortality of people of color have been well-documented. Given these disparities, it is critical that trials for COVID-19 vaccines and therapeutics ensure diverse participation. The few exceptions that have been reported, however, prove that recruitment and retention of underserved populations is possible with effort, planning and intentionality of purpose...

...This week PhRMA published a strong statement embracing equity, denouncing racism and putting forth actionable commitments endorsed by its member companies. PhRMA has expanded its Principles on Conduct of Clinical Trials to emphasize and strengthen the commitment to diverse inclusion in clinical trials. The MRCT Center applauds the seriousness with which the problem of health inequities is being addressed, including the call for investments in workforce development and professional opportunities, in changes in trial design and conduct, in community engagement and partnership, in education and in infrastructure. None of these initiatives will succeed, however, unless we appreciate our interdependencies and common interests. We are all and each responsible and must stand together for change.

* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 11, 2020 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 22, Number 11: E907-980 November 2020

<https://journalofethics.ama-assn.org/issue/caring-native-americans>

Risk Management Ethics

Patients' rights to self-determination or clinicians' professional judgments in some cases deviate from standard of care and challenge risk managers' tendencies to implement routine legal risk-mitigation strategies. Risk managers' roles on care teams are particularly key when patients don't progress clinically, when patients do not feel safe or satisfied with their services, when interventions are not well coordinated, or when care is not safely, efficiently, or equitably executed. Risk managers' collaborations with ethics consultants and clinicians in these cases help individuals and organizations respond well to complex questions at the intersections of professional caregiving, ethics, and law. [Issue PDF](#)

[Reviewed earlier]

American Journal of Infection Control

November 2020 Volume 48 Issue 11 p1287-1414

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

November 2020 Volume 5 9 Issue 5 p621-772

<http://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

November 2020 110(11)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 103, Issue 5, November 2020

<http://www.ajtmh.org/content/journals/14761645/103/5>

[Reviewed earlier]

Annals of Internal Medicine

17 November 2020 Volume 173, Issue 10

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 289, December 2020

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/289/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 28 Nov 2020)

[No new digest content identified]

BMJ Global Health

November 2020 - Volume 5 - 11

<https://gh.bmj.com/content/5/11>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 28 Nov 2020)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 28 Nov 2020)

[A simple clinical score to identify likely hepatitis B vaccination non-responders – data from a retrospective single center study](#)

About 10% of Hepatitis B vaccinated individuals mount no protective antibody levels against the hepatitis B surface antigen (HBs-Ag). Older age at primary immunization, obesity and smoking have previously been...

Authors: Marc A. Meier and Christoph T. Berger

Citation: BMC Infectious Diseases 2020 20:891

Content type: Research article

Published on: 25 November 2020

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 28 Nov 2020)

[Moral structuring of children during the process of obtaining informed consent in clinical and research settings](#)

Informed consent is an important factor in a child's moral structure from which different types of doctor-patient relationships arise. Children's autonomy is currently under discussion in terms of their decent treatment, beyond what doctors and researchers perceive. To describe the influential practices that exist among clinicians and researchers toward children with chronic diseases during the process of obtaining informed consent.

Authors: Anderson Díaz-Pérez, Elkin Navarro Quiroz and Dilia Esther Aparicio Marengo

Content type: Research article

25 November 2020

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 28 Nov 2020)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 28 Nov 2020)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 28 Nov 2020)

[Predictors of immunization coverage among 12–23 month old children in Ethiopia: systematic review and meta-analysis](#)

Immunization is one of modern medicine's greatest achievements in the last three decades. Annually it can prevent nearly 2 to 3 million deaths. Understanding the determinants of effective immunization coverage...

Authors: Tahir Yousuf Nour, Alinoor Mohamed Farah, Omer Moelin Ali, Mohamed Omar Osman, Mowlid Akil Aden and Kalkidan Hassen Abate

Citation: BMC Public Health 2020 20:1803

Content type: Research article

Published on: 26 November 2020

Willingness of female sex workers in Kampala, Uganda to participate in future HIV vaccine trials: a case control study

We anticipate large efficacy trials of novel HIV vaccines that have shown acceptable safety profiles. We determined willingness to participate (WTP) in future HIV vaccine efficacy trials among HIV negative fem...

Authors: Yunia Mayanja, Andrew Abaasa, Gertrude Namale, Matt A. Price and Anatoli Kamali

Citation: BMC Public Health 2020 20:1789

Content type: Research article

Published on: 25 November 2020

The role of the media on maternal confidence in provider HPV recommendation

Despite a growing understanding of the importance of provider HPV recommendation on parental acceptance, U.S. HPV vaccination rates remain suboptimal. Given the prevalence and use of the media for health decis...

Authors: Kimberly K. Walker, Heather Owens and Gregory Zimet

Citation: BMC Public Health 2020 20:1765

Content type: Research article

Published on: 23 November 2020

Personality and individual attitudes toward vaccination: a nationally representative survey in the United States

Although past studies have identified factors associated with individual perceptions of vaccination, limited attention has been paid to the role of personality in individual attitudes toward vaccination. This

Authors: Fang-Yu Lin and Ching-Hsing Wang

Citation: BMC Public Health 2020 20:1759

Content type: Research article

Published on: 23 November 2020

Geographic location of health facility and immunization program performance in Hoima district, western Uganda: a health facility level assessment

Globally, immunization coverage for childhood vaccines is below the immunization target of achieving at least 90% coverage with the pentavalent vaccine. In Uganda, a recent survey shows 80% of districts had po...

Authors: Nicholas Kwikiriza Magambo, Francis Bajunirwe and Fred Bagenda

Citation: BMC Public Health 2020 20:1764

Content type: Research article

Published on: 23 November 2020

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 28 Nov 2020)

[No new digest content identified]

BMJ Open

November 2020 - Volume 10 - 11

<https://bmjopen.bmj.com/content/10/11>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 98, Number 11, November 2020, 725-820

<https://www.who.int/bulletin/volumes/98/11/en/>

[Reviewed earlier]

Child Care, Health and Development

Volume 46, Issue 6 Pages: 651-750 November 2020

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 108, Issue 5 Pages: 897-1106 November 2020

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

November 2020 Volume 42 Issue 11 p2119-2238, e209-e258

<http://www.clinicaltherapeutics.com/current>

[New issue; No digest content identified]

Clinical Trials

Volume 17 Issue 6, December 2020

<https://journals.sagepub.com/toc/ctja/17/5>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 28 Nov 2020]

[**Considerations for planning COVID-19 treatment services in humanitarian responses**](#)

The COVID-19 pandemic has the potential to cause high morbidity and mortality in crisis-affected populations. Delivering COVID-19 treatment services in crisis settings will likely entail complex trade-offs bet...

Authors: Sylvia Garry, Nada Abdelmagid, Louisa Baxter, Natalie Roberts, Olivier le Polain de Waroux, Sharif Ismail, Ruwan Ratnayake, Caroline Favas, Elizabeth Lewis and Francesco Checchi

Citation: Conflict and Health 2020 14:80

Content type: Research in practice

Published on: 25 November 2020

Contemporary Clinical Trials

Volume 97 October 2020

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/97/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 3, Issue 5 / October 2020

<https://www.liebertpub.com/toc/crispr/3/5>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 8, issue 3, September 2020

<https://link.springer.com/journal/40142/volumes-and-issues/8-3>

[Reviewed earlier]

Current Opinion in Infectious Diseases

December 2020 - Volume 33 - Issue 6

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Developing World Bioethics

Volume 20, Issue 3 Pages: 115-171 September 2020

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 30, Issue 7, 2020

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 14 - Issue 3 - June 2020

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 44, Issue 4 Pages: 619-752 October 2020

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 21 Issue 11 5 November 2020

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 26, Number 11—November 2020

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 32 September 2020

<https://www.sciencedirect.com/journal/epidemics/vol/32/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 148 - 2020

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 42, Issue 6 Pages: 1-40 November–December 2020

<https://onlinelibrary.wiley.com/toc/25782363/current>

Video-capture studies • Benefit sharing and genomics research

[Reviewed earlier]

The European Journal of Public Health

Volume 30, Issue 5, October 2020

<https://academic.oup.com/eurpub/issue/30/5>

[Reviewed earlier]

Expert Review of Vaccines

Vol 19 (9) 2020

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 28 Nov 2020]

Research Article metrics AWAITING PEER REVIEW

[Ripple effects of research capacity strengthening: a study of the effects of a project to support test facilities in three African countries towards Good Laboratory Practice certification](#) [version 1; peer review: awaiting peer review]

Sara Begg, Alexandra Wright, Graham Small, Diabate Abdoulaye, William Kisinza, Benjamin Koudou, Sarah Moore, Franklin Masha, Constant Edi, Matthew Kirby, Patrick Kija, Robert Malima, Jason Moore, Imelda Bates

Peer Reviewers Invited

Funder

Bill and Melinda Gates Foundation

PUBLISHED 27 Nov 2020

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 28 Nov 2020]

[No new digest content identified]

Global Health Action

Volume 13, Issue 1 (2020)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 8, No. 3 October 01, 2020

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Public Health

Volume 15, 2020 Issue 12

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 28 Nov 2020]

[No new digest content identified]

Health Affairs

Vol. 39, No. 10 October 2020

<https://www.healthaffairs.org/toc/hlthaff/current>

Children's Health

[Reviewed earlier]

Health and Human Rights

Volume 22, Issue 1, June 2020

<https://www.hhrjournal.org/volume-22-issue-1-june-2020/>

Special Section: Mental Health and Human Rights

[Reviewed earlier]

Health Economics, Policy and Law

Volume 15 - Issue 4 - October 2020

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 35, Issue Supplement_1, November 2020

https://academic.oup.com/heapol/issue/35/Supplement_1

SUPPLEMENT

Health policy and systems research mentoring: Supporting early career women in Low- and Middle-Income Countries

[Supporting early-career mentorship for women in Health Policy and Systems Research: a vital input to building the field](#)

Aku Kwamie, Nanuka Jalaghoia

Health Policy and Planning, Volume 35, Issue Supplement_1, November 2020, Pages i4–i6,

<https://doi.org/10.1093/heapol/czaa105>

[Factors associated with the utilization of inactivated polio vaccine among children aged 12 to 23 months in Kalungu District, Uganda](#)

Mirembe Rachel Faith, Babirye Juliet, Nathan Tumuhamy, Tumwebaze Mathias, Emma Sacks

Health Policy and Planning, Volume 35, Issue Supplement_1, November 2020, Pages i30–i37,

<https://doi.org/10.1093/heapol/czaa099>

[Do social accountability approaches work? A review of the literature from selected low- and middle-income countries in the WHO South-East Asia region](#)

Nahitun Naher, Dina Balabanova, Eleanor Hutchinson, Robert Marten, Roksana Hoque ...

Health Policy and Planning, Volume 35, Issue Supplement_1, November 2020, Pages i76–i96,

<https://doi.org/10.1093/heapol/czaa107>

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 28 Nov 2020]

No new digest content identified]

Human Gene Therapy

Volume 31, Issue 21-22 / November 2020

<https://www.liebertpub.com/toc/hum/31/21-22>

[Reviewed earlier]

Humanitarian Exchange Magazine

Number 78, October 2020

<https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/>

Disability inclusion in humanitarian action

by HPN October 2020

The theme of this edition of Humanitarian Exchange, co-edited with Sherin Alsheikh Ahmed from Islamic Relief Worldwide, is disability inclusion in humanitarian action. Persons with disabilities are not only disproportionately impacted by conflicts, disasters and other emergencies, but also face barriers to accessing humanitarian assistance. At the same time, global commitments and standards and the IASC Guidelines on the inclusion of persons with disabilities in humanitarian action all emphasise how persons with disabilities are also active agents of change. Disability and age-focused organisations have led on testing and demonstrating how inclusion can be done better. Yet despite this progress, challenges to effective inclusion remain.

As Kirstin Lange notes in the lead article, chief among these challenges is humanitarian agencies' lack of engagement with organisations of persons with disabilities. Simone Bula, Elizabeth Morgan and Teresa Thomson look at disability inclusion in humanitarian response in the Pacific, and Kathy Al Jubeh and Alradi Abdalla argue for a 'participation revolution', building on learning from the gender movement. Tchaurea Fleury and Sulayman AbdulMumuni Ujah outline how the Bridge Article 11 training initiative is encouraging constructive exchange between humanitarian and disability actors. The lack of good, disaggregated data is highlighted by Sarah Collinson; Frances Hill, Jim Cranshaw and Carys Hughes emphasise the need for training resources in local languages and accessible formats; and Sophie Van Eetvelt and colleagues report on a review of the evidence on inclusion of people with disabilities and older people.

Rebecca Molyneux and co-authors analyse the findings of a review of a DFID programme in north-east Nigeria, while Carolin Funke highlights the importance of strategic partnerships between disability-focused organisations, drawing on her research in Cox's Bazar. Sherin Alsheikh Ahmed describes Islamic Relief Worldwide's approach to mainstreaming protection and inclusion, while Pauline Thivillier and Valentina Shafina outline IRC's Client Responsive Programming. The edition ends with reflections by Mirela Turcanu and Yves Ngunzi Kahashi on CAFOD's SADI approach.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 16, Issue 9, 2020

<http://www.tandfonline.com/toc/khvi20/current>
[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/content>
[Accessed 28 Nov 2020]
[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>
[Accessed 28 Nov 2020]
[No new digest content identified]

International Health

Volume 12, Issue 6, November 2020
<https://academic.oup.com/inthealth/issue/12/6>
[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 7, No 11 (2020) November 2020
<https://www.ijcmph.com/index.php/ijcmph/issue/view/68>
Table of Contents
[Reviewed earlier]

International Journal of Epidemiology

Volume 49, Issue 4, August 2020
<https://academic.oup.com/ije/issue/49/4>
[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 13 Issue 4 2020
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/13/iss/4>
Table of Contents
[Reviewed earlier]

International Journal of Infectious Diseases

November 2020 Volume 100 p1-512
<https://www.ijidonline.com/current>
Perspective

[**Ending the epidemic of HIV/AIDS by 2030: Will there be an endgame to HIV, or an endemic HIV requiring an integrated health systems response in many countries?**](#)

Yibeltal Assefa, Charles F. Gilks
Published online: September 10, 2020

Original Reports

[Characterizing mothers and children at risk of being under-immunized in India: A latent class analysis approach](#)

Taylor A. Holroyd, Brian Wahl, Madhu Gupta, ... Daniel J. Erchick, Mathuram Santosham, Rupali J. Limaye

Published online: August 26, 2020
p59-66

JAMA

November 24, 2020, Vol 324, No. 20, Pages 2013-2114
<https://jamanetwork.com/journals/jama/currentissue>

Research Letter

[COVID-19 and Excess All-Cause Mortality in the US and 18 Comparison Countries](#)

Alyssa Bilinski, MSc; Ezekiel J. Emanuel, MD, PhD

free access has active quiz

JAMA. 2020;324(20):2100-2102. doi:10.1001/jama.2020.20717

This Viewpoint compares the COVID-19 per capita overall and excess mortality rates in the US vs that of 18 OECD countries and the timing of any increases in excess mortality between February and September 2020.

Viewpoint

[Is It Lawful and Ethical to Prioritize Racial Minorities for COVID-19 Vaccines?](#)

Harald Schmidt, PhD; Lawrence O. Gostin, JD; Michelle A. Williams, ScD

free access has active quiz has multimedia has audio

JAMA. 2020;324(20):2023-2024. doi:10.1001/jama.2020.20571

This Viewpoint considers how COVID-19 vaccines can be distributed strategically, ethically, and legally given conflicts between consensus public health recommendations to prioritize allocation to disadvantaged racial and ethnic minorities and laws discouraging explicit consideration of race in policy decisions.

[Scientific and Ethical Principles Underlying Recommendations From the Advisory Committee on Immunization Practices for COVID-19 Vaccination Implementation](#)

Beth P. Bell, MD, MPH; José R. Romero, MD; Grace M. Lee, MD, MPH

free access has active quiz

JAMA. 2020;324(20):2025-2026. doi:10.1001/jama.2020.20847

This Viewpoint summarizes the principles guiding coronavirus disease 2019 (COVID-19) vaccine recommendations made by the Advisory Committee on Immunization Practices (ACIP), a nongovernment advisory standing committee that counsels the Centers for Disease Control and Prevention on US population vaccine use, emphasizing that any final recommendations await phase 3 safety and efficacy data from ongoing trials.

[Answering Key Questions About COVID-19 Vaccines](#)

Jesse L. Goodman, MD, MPH; John D. Grabenstein, RPh, PhD; M. Miles Braun, MD, MPH

free access has active quiz

JAMA. 2020;324(20):2027-2028. doi:10.1001/jama.2020.20590

This Viewpoint offers provisional answers to common questions the public will have about approved COVID-19 vaccines, including what they can expect regarding its effectiveness and safety, trustworthiness of the approval process, and whether society can return to normal once sufficient numbers of people are immunized.

[Herd Immunity and Implications for SARS-CoV-2 Control](#)

Saad B. Omer, MBBS, MPH, PhD; Inci Yildirim, MD, PhD, MSc; Howard P. Forman, MD, MBA
free access has active quiz has multimedia has audio

JAMA. 2020;324(20):2095-2096. doi:10.1001/jama.2020.20892

This JAMA Insights Clinical Update discusses herd immunity in the context of the COVID-19 pandemic and explains the herd immunity threshold as a function of transmissibility (R_0), the role of an effective vaccine and vaccination program in sustaining herd immunity, and the risks of an infection-based herd immunity approach.

[Expanding Use of Clinical Genome Sequencing and the Need for More Data on Implementation](#)

Kathryn A. Phillips, PhD; Michael P. Douglas, MS; Deborah A. Marshall, PhD
has audio

JAMA. 2020;324(20):2029-2030. doi:10.1001/jama.2020.19933

This Viewpoint discusses the importance of understanding how next-generation genomic sequencing is being implemented—for whom noninvasive prenatal testing, whole-exome and -genome sequencing for suspected genetic disorders, and tumor sequencing is being used and who is paying for it—as precondition for knowing how the technologies can best serve patients.

JAMA Network

[COVID-19 Update November 28, 2020](#)

These articles on COVID-19 were published across the JAMA Network in the last week.

[Reviewed earlier]

JAMA Pediatrics

November 2020, Vol 174, No. 11, Pages 1017-1124

<http://archpedi.jamanetwork.com/issue.aspx>

[Reviewed earlier]

JBI Evidence Synthesis

November 2020 - Volume 18 - Issue 11

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

December 2020 Volume 67 Issue 6p733-880

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 69 (2020)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 45, issue 6, December 2020

<https://link.springer.com/journal/10900/volumes-and-issues/45-6>

Articles

[Reviewed earlier]

Journal of Development Economics

Volume 147 November 2020

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/147/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 15 Issue 5, December 2020

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

November 2020 - Volume 74 - 11

<https://jech.bmj.com/content/74/11>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 13, Issue 4 Pages: 251-324 November 2020

<https://onlinelibrary.wiley.com/toc/17565391/current>

EDITORIAL

[**Evidence synthesis and methodological research on evidence in medicine—Why it really is research and it really is medicine**](#)

[Livia Puljak](#)

Pages: 253-254

First Published: 03 November 2020

REVIEWS

[**Analytics with artificial intelligence to advance the treatment of acute respiratory distress syndrome**](#)

[Zhongheng Zhang et al](#)

Pages: 301-312

First Published: 13 November 2020

Abstract

Artificial intelligence (AI) has found its way into clinical studies in the era of big data. Acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) is a clinical syndrome that encompasses a heterogeneous population. Management of such heterogeneous patient population is a big challenge for clinicians. With accumulating ALI datasets being publicly available, more knowledge could be discovered with sophisticated analytics. We reviewed literatures with big data analytics to understand the role of AI for improving the caring of patients with ALI/ARDS. Many studies have utilized the electronic medical records (EMR) data for the identification and prognostication of ARDS patients. As increasing number of ARDS clinical trials data is open to public, secondary analysis on these combined datasets provide a powerful way of finding solution to clinical questions with a new perspective. AI techniques such as Classification and Regression Tree (CART) and artificial neural networks (ANN) have also been successfully used in the investigation of ARDS problems. Individualized treatment of ARDS could be implemented with a support from AI as we are now able to classify ARDS into many subphenotypes by unsupervised machine learning algorithms. Interestingly, these subphenotypes show different responses to a certain intervention. However, current analytics involving ARDS have not fully incorporated information from omics such as transcriptome, proteomics, daily activities and environmental conditions. AI technology is assisting us to interpret complex data of ARDS patients and enable us to further improve the management of ARDS patients in future with individual treatment plans.

Journal of Global Ethics

Volume 16, Issue 2, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 31, Number 4, November 2020

<https://muse.jhu.edu/issue/42831>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 22, issue 6, December 2020

<https://link.springer.com/journal/10903/volumes-and-issues/22-6>

[New issue, No digest content identified]

Journal of Immigrant & Refugee Studies

Volume 18, 2020_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 222, Issue 3, 1 August 2020
<https://academic.oup.com/jid/issue/222/3>
[Reviewed earlier]

Journal of Medical Ethics

November 2020 - Volume 46 - 11
<http://jme.bmj.com/content/current>
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 7, Issue 4 (2020)
<https://digitalrepository.aurorahealthcare.org/jpcrr/>
[Reviewed earlier]

Journal of Pediatrics

November 2020 Volume 226 p1-322
<http://www.jpeds.com/current>
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>
[Accessed 28 Nov 2020]
[No new digest content identified]

Journal of Public Health Management & Practice

November/December 2020 - Volume 26 - Issue 6
<https://journals.lww.com/jphmp/pages/currenttoc.aspx>
[Reviewed earlier]

Journal of Public Health Policy

Volume 41, issue 4, December 2020
<https://link.springer.com/journal/41271/volumes-and-issues/41-4>
[Reviewed earlier]

Journal of Refugee & Global Health

Volume 3, Issue 1 (2020)
<https://ir.library.louisville.edu/rgh/>
[Reviewed earlier]

Journal of the Royal Society – Interface

November 2020 Volume 17 Issue 172
<https://royalsocietypublishing.org/toc/rsif/current>
[Reviewed earlier]

Journal of Travel Medicine

Volume 27, Issue 7, October 2020
<https://academic.oup.com/jtm/issue/27/7>
[Reviewed earlier]

Journal of Virology

November 2020; Volume 94, Issue 21
<http://jvi.asm.org/content/current>
[Reviewed earlier]

The Lancet

Nov 28, 2020 Volume 396 Number 10264 p1703-1776
<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

[Maintaining the HIV response in a world shaped by COVID-19](#)

The Lancet

Comment

[Emergency use authorisation for COVID-19 vaccines: lessons from Ebola](#)

Maxwell J Smith, Samuel Ujewe, Rachel Katz, Ross E G Upshur

Russia and China have begun COVID-19 vaccinations outside of clinical trials. This move has been met with widespread criticism because the safety profiles of these candidate COVID-19 vaccines remain uncertain without data from phase 3 trials.^{1,2} Emergency use authorisations—a regulatory mechanism that enables the public to gain access to promising investigational medical products when those products have not yet received regulatory approval and licensure³—have previously been used for unlicensed vaccines in public health emergencies and can be ethically justified provided that certain conditions are met. So why have the actions of Russia and China drawn such criticism? And how can other national regulatory authorities ensure future emergency use authorisations for COVID-19 vaccines are issued in a way that is scientifically and ethically sound? Experience of emergency use authorisations for investigational Ebola virus vaccines in Guinea and the Democratic Republic of the Congo (DRC) can elucidate key lessons that can guide ethical emergency use authorisations for COVID-19 vaccines...

The Lancet Child & Adolescent Health

Nov 2020 Volume 4 Number 11 p795-852, e40-e44
<https://www.thelancet.com/journals/lanchi/issue/current>
[Reviewed earlier]

Lancet Digital Health

Nov 2020 Volume 2 Number 11 e561-e628
<https://www.thelancet.com/journals/landig/issue/current>
[Reviewed earlier]

Lancet Global Health

Nov 2020 Volume 8 Number 11 e1352-e1443
<http://www.thelancet.com/journals/langlo/issue/current>
[Reviewed earlier]

Lancet Infectious Diseases

Nov 2020 Volume 20 Number 11 p1217-1348, e275-e297
<http://www.thelancet.com/journals/laninf/issue/current>
[Reviewed earlier]

Lancet Public Health

Nov 2020 Volume 5 Number 11 e568-e627
<https://www.thelancet.com/journals/lanpub/issue/current>
[Reviewed earlier]

Lancet Respiratory Medicine

Nov 2020 Volume 8 Number 11 p1061-1158, e78-e86
<http://www.thelancet.com/journals/lanres/issue/current>
[Reviewed earlier]

Maternal and Child Health Journal

Volume 24, issue 11, November 2020
<https://link.springer.com/journal/10995/volumes-and-issues/24-11>
Special Issue : Deaf Child Health in an International Context
[Reviewed earlier]

Medical Decision Making (MDM)

Volume 40 Issue 8, November 2020
<http://mdm.sagepub.com/content/current>
[New issue; No digest content identified]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy
Volume 98, Issue 3 Pages: 619-1020 September 2020
<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Nature

Volume 587 Issue 7835, 26 November 2020

http://www.nature.com/nature/current_issue.html

Editorial | 25 November 2020

[UNESCO must reform to stay relevant — and reconnect people through science](#)

At 75, the UN agency with a focus on science cooperation is fighting for its future role.

Editorial | 24 November 2020

[The COVID vaccine challenges that lie ahead](#)

As positive results emerge at last, researchers must help the world to address vaccine hesitancy, supply logistics and pricing.

Nature Biotechnology

Volume 38 Issue 11, November 2020

<https://www.nature.com/nbt/volumes/38/issues/11>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 28 Nov 2020)

[No new digest content identified]

Nature Genetics

Volume 52 Issue 11, November 2020

<https://www.nature.com/ng/volumes/52/issues/11>

[Reviewed earlier]

Nature Medicine

Volume 26 Issue 11, November 2020

<https://www.nature.com/nm/volumes/26/issues/11>

[New issue; No digest content identified]

Nature Reviews Genetics

Volume 21 Issue 11, November 2020

<https://www.nature.com/nrg/volumes/21/issues/11>

[Reviewed earlier]

Nature Reviews Immunology

Volume 20 Issue 11, November 2020

<https://www.nature.com/nri/volumes/20/issues/11>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 19 Issue 11, November 2020

<https://www.nature.com/nrd/volumes/19/issues/11>

[Reviewed earlier]

New England Journal of Medicine

November 26, 2020 Vol. 383 No. 22

<http://www.nejm.org/toc/nejm/medical-journal>

Perspective

[Banning Genetic Discrimination in Life Insurance — Time to Follow Florida’s Lead](#)

Mark A. Rothstein, J.D.,

and Kyle B. Brothers, M.D., Ph.D.

Fear of discrimination by life insurance companies has been an obstacle to progress in the use of genetic technologies in medicine and research. A new Florida law will allow residents to undergo genetic testing without fear of the financial consequences of results.

Perspective

[Trustworthiness before Trust — Covid-19 Vaccine Trials and the Black Community](#)

Rueben C. Warren, D.D.S., Dr.P.H., M.Div., Lachlan Forrow, M.D., David Augustin Hodge, Sr., D.Min., Ph.D., and Robert D. Truog, M.D.

... What are the barriers to greater participation of Black people in Covid-19 trials? Although they are multiple, a critical factor is the deep and justified lack of trust that many Black Americans have for the health care system in general and clinical research in particular. This distrust is often traced to the legacy of the infamous syphilis study at Tuskegee, in which investigators withheld treatment from hundreds of Black men in order to study the natural history of the disease. But the distrust is far more deeply rooted, in centuries of well-documented examples of racist exploitation by American physicians and researchers.²

Pediatrics

Vol. 146, Issue 5 1 Nov 2020

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

Pharmaceutics

Volume 12, Issue 7 (July 2020) – 97 articles

<https://www.mdpi.com/1999-4923/12/7>

[Reviewed earlier]

PharmacoEconomics

Volume 38, issue 11, November 2020

<https://link.springer.com/journal/40273/volumes-and-issues/38-11>

[Reviewed earlier]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 28 Nov 2020)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 28 Nov 2020)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 28 Nov 2020)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

Research Article

[Hepatitis B vaccination status and knowledge, attitude, and practice regarding Hepatitis B among preclinical medical students of a medical college in Nepal](#)

Dhan Bahadur Shrestha, Manita Khadka, Manoj Khadka, Prarthana Subedi, Subashchandra Pokharel, Bikash Bikram Thapa

Research Article | published 23 Nov 2020 PLOS ONE

<https://doi.org/10.1371/journal.pone.0242658>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 28 Nov 2020]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States of America

<http://www.pnas.org/content/early/>

Articles

[Ethics in field experimentation: A call to establish new standards to protect the public from unwanted manipulation and real harms](#)

Rose McDermott and Peter K. Hatemi

PNAS first published November 23, 2020. <https://doi.org/10.1073/pnas.2012021117>

Abstract

In 1966, Henry Beecher published his foundational paper "Ethics and Clinical Research," bringing to light unethical experiments that were routinely being conducted by leading universities and

government agencies. A common theme was the lack of voluntary consent. Research regulations surrounding laboratory experiments flourished after his work. More than half a century later, we seek to follow in his footsteps and identify a new domain of risk to the public: certain types of field experiments. The nature of experimental research has changed greatly since the Belmont Report. Due in part to technological advances including social media, experimenters now target and affect whole societies, releasing interventions into a living public, often without sufficient review or controls. A large number of social science field experiments do not reflect compliance with current ethical and legal requirements that govern research with human participants. Real-world interventions are being conducted without consent or notice to the public they affect. Follow-ups and debriefing are routinely not being undertaken with the populations that experimenters injure. Importantly, even when ethical research guidelines are followed, researchers are following principles developed for experiments in controlled settings, with little assessment or protection for the wider societies within which individuals are embedded. We strive to improve the ethics of future work by advocating the creation of new norms, illustrating classes of field experiments where scholars do not appear to have recognized the ways such research circumvents ethical standards by putting people, including those outside the manipulated group, into harm's way.

[The science of deep learning](#)

Richard Baraniuk, David Donoho, and Matan Gavish
PNAS first published November 23, 2020.
<https://doi.org/10.1073/pnas.2020596117>

Prehospital & Disaster Medicine

Volume 35 - Issue 6 - December 2020

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[New issue; No digest content identified]

Preventive Medicine

Volume 140, November 2020

<https://www.sciencedirect.com/journal/preventive-medicine/vol/140/suppl/C>

Behavior Change, Health, Health Disparities 2020: Some Current Challenges in Tobacco Control and Regulatory Science

Edited by Stephen T. Higgins

[New issue; No digest content identified]

Proceedings of the Royal Society B

11 November 2020 Volume 287 Issue 1938

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 188 Pages A1-A2, 1-54 (November 2020)

<https://www.sciencedirect.com/journal/public-health/vol/188/suppl/C>

[Reviewed earlier]

Public Health Ethics

IN PROGRESS

Volume 13, Issue 1, April 2020

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 135 Issue 6, November/December 2020

<https://journals.sagepub.com/toc/phrg/135/6>

[Reviewed earlier]

Qualitative Health Research

Volume 30 Issue 14, December 2020

<http://qhr.sagepub.com/content/current>

[Reviewed earlier]

Research Ethics

Volume 16 Issue 3-4, July-October 2020

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 28 Nov 2020]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest articles

23 Nov 2020

[**Open public health: the way not to leave anyone behind**](#)

Opinion and analysis | Spanish |

Risk Analysis

Volume 40, Issue 11 Pages: 2301-2477 November 2020

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 28 Nov 2020]

[No new digest content identified]

Science

27 November 2020 Vol 370, Issue 6520

<http://www.sciencemag.org/current.dtl>

[New issue; No digest content identified]

Science Translational Medicine

25 November 2020 Vol 12, Issue 571

<https://stm.sciencemag.org/>

[New issue; No digest content identified]

Social Science & Medicine

Volume 264 November 2020

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/264/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 28 Nov 2020]

<https://stm.sciencemag.org/>

[o new digest content identified]

Travel Medicine and Infectious Diseases

Volume 37 September–October 2020

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/37/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 25, Issue 10 Pages: i-iv, 1167-1305 October 2020

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 38, Issue 51 Pages 8055-8246 (3 December 2020)

<https://www.sciencedirect.com/journal/vaccine/vol/38/issue/51>

Discussion No access

[Vaccine mandates in the US and Australia: balancing benefits and burdens for children and physicians](#)

Mark C. Navin, Margie Danchin
Pages 8075-8077

Research article Full text access

[The demand for a COVID-19 vaccine in Ecuador](#)

Oscar Sarasty, Carlos E. Carpio, Darren Hudson, Patricia A. Guerrero-Ochoa, Ivan Borja
Pages 8090-8098

Research article Full text access

[The demand for a COVID-19 vaccine in Ecuador](#)

Oscar Sarasty, Carlos E. Carpio, Darren Hudson, Patricia A. Guerrero-Ochoa, Ivan Borja
Pages 8090-8098

Research article Full text access

[The demand for a COVID-19 vaccine in Ecuador](#)

Oscar Sarasty, Carlos E. Carpio, Darren Hudson, Patricia A. Guerrero-Ochoa, Ivan Borja
Pages 8090-8098

Vaccines — Open Access Journal

<http://www.mdpi.com/journal/vaccines>

(Accessed 28 Nov 2020)

Open Access Article

[The Magnitude and Determinants of Missed Opportunities for Childhood Vaccination in South Africa](#)

by [Dudzile Ndwandwe](#) et al

Vaccines 2020, 8(4), 705; <https://doi.org/10.3390/vaccines8040705> - 25 Nov 2020

Viewed by 160

Abstract

Missed opportunities for vaccination (MOV) may be among the factors responsible for suboptimal vaccination coverage in South Africa. However, the magnitude and determinants of MOV in the country are not known. Thus, this study seeks to assess the prevalence and determinants of MOV [...]

Open Access Article

[Vaccination Attitude and Communication in Early Settings: An Exploratory Study](#)

by [Noemi Mereu](#) et al

Vaccines 2020, 8(4), 701; <https://doi.org/10.3390/vaccines8040701> - 20 Nov 2020

Viewed by 274

Abstract

Background: This study assesses attitudes towards vaccination in mothers of new-born babies and explores its association with different exposures to communication. Methods: Data were collected through questionnaires administered by means of interviews. Results: Data highlighted that 20% of mothers showed an orientation towards [...]

Value in Health

November 2020 Volume 23 Issue 11 p1403-1522
<https://www.valueinhealthjournal.com/current>
[Reviewed earlier]

* * * *

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

The Atlantic

<http://www.theatlantic.com/magazine/>

Accessed 28 Nov 2020

Ideas

Your Individually Rational Choice Is Collectively Disastrous

Stopping the virus from spreading requires us to override our basic intuitions.

November 24, 2020

Yascha Mounk

.. Many factors help explain America's abject failure to contain the pandemic. A good number of them can be traced back to Donald Trump. But many democracies with able leaders, such as Germany and Canada, are also struggling to contain the virus, so pointing to the president's lies and incompetence isn't sufficient.

One major problem is that stopping the virus from spreading requires us to override our basic intuitions. Three cognitive biases make it hard for us to avoid actions that put us in great collective danger...

BBC

<http://www.bbc.co.uk/>

Accessed 28 Nov 2020

[No new, unique, relevant content]

The Economist

<http://www.economist.com/>

Accessed 28 Nov 2020

United States Nov 28th 2020 edition

America will be the first country to roll out a covid-19 vaccine

Here is how the federal government and states plan to do it

Financial Times

<https://www.ft.com/>

Accessed 28 Nov 2020

Coronavirus treatment

[UK set to approve Pfizer-BioNTech Covid vaccine within days](#)

...The UK is poised to become the first western country to approve a Covid-19 vaccine, with the independent regulator set to grant approval within days. Deliveries of the vaccine developed by BioNTech...

November 28, 2020

Analysis Pharmaceuticals sector

[Covid vaccines offer Big Pharma a chance of rehabilitation](#)

November 27, 2020

Analysis Coronavirus treatment

[How AstraZeneca and Oxford found their vaccine under fire](#)

November 27, 2020

Forbes

<http://www.forbes.com/>

Accessed 28 Nov 2020

Breaking | 5 hours ago

[Biden Creates Diverse Covid-19 Advisory Board To Contrast With Trump](#)

Trump's task force is primarily composed of political appointees with portfolios ranging from the economy to national security to housing.

By [Andrew Solender](#) Forbes Staff

Foreign Affairs

<http://www.foreignaffairs.com/>

Accessed 28 Nov 2020

[No new, unique, relevant content]

Foreign Policy

<http://foreignpolicy.com/>

Accessed 28 Nov 2020

[No new, unique, relevant content]

The Guardian

<http://www.guardiannews.com/>

Accessed 28 Nov 2020

[No new, unique, relevant content]

New Yorker

<http://www.newyorker.com/>

Accessed 28 Nov 2020

[No new, unique, relevant content]

New York Times

<http://www.nytimes.com/>

Accessed 28 Nov 2020

Europe

[**Britain Set to Leap Ahead in Approving Vaccines**](#)

Regulators may approve the troubled AstraZeneca vaccine and the American-made Pfizer shot weeks before the U.S. does so.

By Benjamin Mueller Nov. 27

World

[**The military's role in a vaccine will be strictly behind the scenes, despite Trump's claims.**](#)

By Jennifer Steinhauer Nov. 27

Science

[**The Virus Won't Stop Evolving When the Vaccine Arrives**](#)

The coronavirus is not a shape shifter like the flu virus, but it could become vaccine resistant over time. That prompts researchers to urge vigilance.

By James Gorman and Carl Zimmer Nov. 27

Business

[**After Admitting Mistake, AstraZeneca Faces Difficult Questions About Its Vaccine**](#)

Some trial participants only got a partial dose of AstraZeneca's vaccine. Experts said the company's spotty disclosures have eroded confidence.

By Rebecca Robbins and Benjamin Mueller Nov. 25

World

[**A Russian vaccine maker reports positive results based on an incomplete trial.**](#)

The results were based on an unspecified small group of volunteers during the ongoing Phase 3 trial of the vaccine.

By Andrew E. Kramer

Washington Post

<https://www.washingtonpost.com/>

Opinion by Editorial Board

[**The U.S. has ensured its supplies of coronavirus vaccine. Now it must help provide them to poor**](#)

Nov 26, 2020

THE WORLD HEALTH Organization's director-general, Dr. Tedros Adhanom Ghebreyesus, warned in August that no country could afford to go it alone in fighting the pandemic. Nations already depend on global supply chains for everything from diagnostic testing to personal protective equipment, he said, and they must avoid "vaccine nationalism" when it comes to the most powerful tool to fight covid-19. When the Group of 20 leaders held their virtual summit meeting last weekend, they again declared their intent not to hoard lifesaving vaccines, saying, "We will spare no effort to ensure their affordable and equitable access for all people."

But as vaccines come closer to reality, wealthy nations of the world have already taken care of their own needs and signed contracts to buy up hundreds of millions of vaccine doses. And the poor? A global risk-sharing procurement initiative to ensure fair and equitable access to vaccines, the Covax Facility, could bring them protection, but only if it can get sufficient funding in 2021. This is the world's

best chance to help the poorest populations confront the pandemic, being led by the WHO, the Coalition for Epidemic Preparedness Innovations and Gavi, the Vaccine Alliance.

As it currently stands, 92 lower-income economies will be supported by the financing mechanism in Covax, the Advanced Market Commitment (AMC). Ninety-seven higher-income economies have signed up as self-financing members of the Covax Facility. The idea is to pool vaccine buying power and ensure distribution for all countries, including the less developed nations, with a goal of obtaining 2 billion doses to protect 20 percent of their populations by the end of 2021, enough to cover front-line health-care workers and the most vulnerable. Negotiations for the shots are underway with manufacturers. To make this initiative work, according to the WHO, there is an urgent need for \$7.8 billion next year from international donors, including \$5 billion for the 92 lower-income countries, and additional funds to help them set up distribution systems, a demanding task. All of that funding remains to be raised.

China and Russia are developing vaccines, too. They have their own national regulatory process, but for their vaccines to be used globally through the Covax Facility they would have to meet international standards through WHO review of quality, safety and impact on disease. They could distribute the vaccines on their own. China has joined Covax as a participant, allowing it to procure doses from the facility, but Russia has not.

Among the big donors to the AMC are the United Kingdom, Canada, Germany and Saudi Arabia. President-elect Joe Biden should commit the United States, too. A \$200 million donation would amount to only 2 percent of spending on Operation Warp Speed. And we hope Mr. Biden will rapidly return the United States to the WHO.

The world's wealthiest countries are on the verge of a science triumph with the arrival of an effective vaccine in less than a year. But in this moment of need, the haves should also extend a hand to the have-nots. As Dr. Tedros said in August, "No one is safe until everyone is safe."

[EU says first virus vaccinations possible by Christmas](#)

Associated Press · Nov 25, 2020

* * * *

[Think Tanks et al](#)

Brookings

<http://www.brookings.edu/>

Accessed 28 Nov 2020

[No new relevant content]

Center for Global Development [to 28 Nov 2020]

<http://www.cgdev.org/page/press-center>

November 25, 2020

[Certificate of COVID Vaccination: Can We Do Better than the Yellow Card?](#)

Can technology help? At the most basic level, a COVID ID would be a digitized version of the Yellow Card, the paper-based International Certificate of Vaccination or Prophylaxis that many international travelers carry with them traveling to and from high-risk areas of the world.

Alan Gelb and Anit Mukherjee

November 25, 2020

The Domestic Allocation Of COVID-19 Vaccines in Low-and Middle-Income Countries, Who Goes First?

As COVID-19 vaccines begin to emerge, policymakers around the world are feeling buoyant. Although governments will be the initial recipients of vaccines, their decisions on how to distribute these among their populations will be fundamental for the ultimate recipients: individuals.

Vageesh Jain

Chatham House [to 28 Nov 2020]

<https://www.chathamhouse.org/>

[No new relevant content]

CSIS

<https://www.csis.org/>

Accessed 28 Nov 2020

[No new relevant content]

Council on Foreign Relations

<http://www.cfr.org/>

Accessed 28 Nov 2020

[No new relevant content]

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 28 Nov 2020

[No new relevant content]

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health,

human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine, and an operating affiliation with the Vaccine Education Center of Children’s Hospital of Philadelphia [CHOP].

Support for this service is provided by the Bill & Melinda Gates Foundation; PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi Pasteur U.S., Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * *
* * * * *